LUND, Sweden, Sept. 28, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, will present preclinical safety data for the drug candidate ATOR-1017 at the 4th...
from PR Newswire: //https://ift.tt/2Olb8Zs
No comments:
Post a Comment